Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
The Lancet. Oncology|December 5, 2024
Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysisPanos Kanavos, Erica Visintin, Aris AngelisSocial Science & Medicine (1982)|July 14, 2023
Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countriesPanos Kanavos, Erica Visintin, Arianna GentiliniHealth Policy (Amsterdam, Netherlands)|September 20, 2018
Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countriesErica Visintin, Michela Tinelli, Panos KanavosPharmacoeconomics - Open|November 30, 2021
Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 CountriesAnna-Maria Fontrier, Erica Visintin, Panos KanavosHealth Economics, Policy, and Law|September 7, 2019
Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods studyElena Nicod, Laia Maynou, Erica Visintin, et al.Health Economics, Policy, and Law|September 9, 2025
Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countriesFilippos Papadopoulos, Erica Visintin, Ilias Kyriopoulos, et al.Globalization and Health|December 3, 2014
The economic burden of diabetes in India: a review of the literatureCharles A K Yesudian, Mari Grepstad, Erica Visintin, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2017
Using IMPrESS to guide policy change in multiple sclerosisMichela Tinelli, Panos Kanavos, Olina Efthymiadou, et al.Pageof 1